Why the study?
Despite widespread COVID-19 vaccine use, research on the association between vaccines and cerebrovascular venous sinus thrombosis in diverse populations is limited.
Are vaccines associated with an increased risk of cerebrovascular venous sinus thrombosis?
Are vaccines associated with an increased risk of cerebrovascular venous sinus thrombosis?
Ad5-vectored COVID-19 vaccines are associated with a significantly increased reporting odds ratio for cerebrovascular venous sinus thrombosis, with risk increasing in older age groups.
Despite widespread coronavirus disease 2019 (COVID-19) vaccine use, research on the association between vaccines and cerebrovascular venous sinus thrombosis (CVST) in diverse populations is limited. This study aimed to address this gap. Data from the World Health Organization pharmacovigilance database (1968-2024; total reports = 8,909,484) were used. Reporting odds ratios (RORs) and information components (ICs) were calculated to assess the association between each drug and CVST. In total, 851 cases were identified as vaccine-associated CVST, of which 527 (61.93%) occurred in female patients. Only Ad5-vectored COVID-19 vaccines had the highest ROR and IC value with CVST (ROR, 4.78; 95% confidence interval, 4.34-5.28; IC, 2.15). The risk of CVST increased with age, with the 45-64-years age group having an IC of 1.35, while the 65 years and older group had a higher IC of 2.08. The findings highlight the need for clinicians to recognize the potential risks of CVST and prioritize rigorous monitoring and research to ensure patient safety.
No takes yet. Share an insight, caveat, or question.
Cho et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: